| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Endocrine Cell Biology (D.W.K., Y.S.J., H.S.J., H.K.C., J.H.S., K.C.P., S.H.P., J.H.H., S.Y.R., M.S.), National Research Laboratory Program, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon 301-721, Korea; Department of Biochemistry (G.R.K.), Seonam University College of Medicine, Namwon 590-711, Korea; Laboratory of Radiation Experimental Therapeutics (S.-J.L.), Korea Institute of Radiological and Medical Sciences, Seoul 139-706, Korea; and Protein Therapeutics Research Center (K.-W.J.), Korea Research Institute of Bioscience and Biotechnology, Yusonku Daejeon 305-333, Korea
Address all correspondence and requests for reprints to: Minho Shong, Laboratory of Endocrine Cell Biology, Department of Internal Medicine, Chungnam National University School of Medicine, 640 Daesadong Chungku Daejon 301-721 Korea. E-mail: minhos{at}cnu.ac.kr.
Context: The oncogenic RET/PTC tyrosine kinase causes papillary thyroid cancer (PTC). The use of inhibitors specific for RET/PTC may be useful for targeted therapy of PTC.
Objective: The objective of the study was to evaluate the efficacies of the recently developed kinase inhibitors SU11248, SU5416, and SU6668 in inhibition of RET/PTC.
Design: SU11248, SU5416, and SU6668 were synthesized, and their inhibitory potencies were evaluated using an in vitro RET/PTC kinase assay. The inhibitory effects of the compounds on RET/PTC were evaluated by quantifying the autophosphorylation of RET/PTC, signal transducer and activator of transcription (STAT)-3 activation, and the morphological reversal of RET/PTC-transformed cells.
Results: An in vitro kinase assay revealed that SU5416, SU6668, and SU11248 inhibited phosphorylation of the synthetic tyrosine kinase substrate peptide E4Y by RET/PTC3 in a dose-dependent manner with IC50 of approximately 944 nM for SU5416, 562 nM for SU6668, and 224 nM for SU11248. Thus, SU11248 effectively inhibits the kinase activity of RET/PTC3. RET/PTC-mediated Y705 phosphorylation of STAT3 was inhibited by addition of SU11248, and the inhibitory effects of SU11248 on the tyrosine phosphorylation and transcriptional activation of STAT3 were very closely correlated with decreased autophosphorylation of RET/PTC. SU11248 caused a complete morphological reversion of transformed NIH-RET/PTC3 cells and inhibited the growth of TPC-1 cells that have an endogenous RET/PTC1.
Conclusion: SU11248 is a highly effective tyrosine kinase inhibitor of the RET/PTC oncogenic kinase.
This article has been cited by other articles:
 |
|
 |
|
  C. L. Bello, M. Mulay, X. Huang, S. Patyna, M. Dinolfo, S. Levine, A. Van Vugt, M. Toh, C. Baum, and L. Rosen Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib Clin. Cancer Res., November 15, 2009; 15(22): 7045 - 7052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Demetri, M. C. Heinrich, J. A. Fletcher, C. D.M. Fletcher, A. D. Van den Abbeele, C. L. Corless, C. R. Antonescu, S. George, J. A. Morgan, M. H. Chen, et al. Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure Clin. Cancer Res., September 15, 2009; 15(18): 5902 - 5909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. DePrimo, X. Huang, M. E. Blackstein, C. R. Garrett, C. S. Harmon, P. Schoffski, M. H. Shah, J. Verweij, C. M. Baum, and G. D. Demetri Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure Clin. Cancer Res., September 15, 2009; 15(18): 5869 - 5877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Woyach and M. H Shah New therapeutic advances in the management of progressive thyroid cancer Endocr. Relat. Cancer, September 1, 2009; 16(3): 715 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Escudier, J. Roigas, S. Gillessen, U. Harmenberg, S. Srinivas, S. F. Mulder, G. Fountzilas, C. Peschel, P. Flodgren, E. C. Maneval, et al. Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma J. Clin. Oncol., September 1, 2009; 27(25): 4068 - 4075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Blay Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib Ann. Onc., August 12, 2009; (2009) mdp291v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Sherman Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1493 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J P. Couto, H Prazeres, P Castro, J Lima, V Maximo, P Soares, and M Sobrinho-Simoes How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer J. Clin. Pathol., May 1, 2009; 62(5): 414 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Sternberg Expanding the boundaries of clinical practice: building on experience with targeted therapies Ann. Onc., May 1, 2009; 20(suppl_1): i1 - i6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. Blay New paradigms in gastrointestinal stromal tumour management Ann. Onc., May 1, 2009; 20(suppl_1): i18 - i24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Houk, C. L. Bello, D. Kang, and M. Amantea A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients Clin. Cancer Res., April 1, 2009; 15(7): 2497 - 2506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Heinrich, R. G. Maki, C. L. Corless, C. R. Antonescu, A. Harlow, D. Griffith, A. Town, A. Mckinley, W.-B. Ou, J. A. Fletcher, et al. Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor J. Clin. Oncol., November 20, 2008; 26(33): 5352 - 5359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Tomoda, F. Moatamed, F. Naeim, J. M. Hershman, and M. Sugawara Indomethacin Inhibits Cell Growth of Medullary Thyroid Carcinoma by Reducing Cell Cycle Progression into S Phase Experimental Biology and Medicine, November 1, 2008; 233(11): 1433 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. van Cruijsen, A. A.M. van der Veldt, L. Vroling, D. Oosterhoff, H. J. Broxterman, R. J. Scheper, G. Giaccone, J. B.A.G. Haanen, A. J.M. van den Eertwegh, E. Boven, et al. Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival Clin. Cancer Res., September 15, 2008; 14(18): 5884 - 5892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Kelleher and R. McDermott Response to Sunitinib in Medullary Thyroid Cancer Ann Intern Med, April 1, 2008; 148(7): 567 - 567. [Full Text] [PDF]
|
|
|
|
|
|
E.-M. Duerr, Y. Mizukami, A. Ng, R. J Xavier, H. Kikuchi, V. Deshpande, A. L Warshaw, J. Glickman, M. H Kulke, and D. C Chung Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis Endocr. Relat. Cancer, March 1, 2008; 15(1): 243 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Kim, H. K. Chung, K. C. Park, J. H. Hwang, Y. S. Jo, J. Chung, D. V. Kalvakolanu, N. Resta, and M. Shong Tumor Suppressor LKB1 Inhibits Activation of Signal Transducer and Activator of Transcription 3 (STAT3) by Thyroid Oncogenic Tyrosine Kinase Rearranged in Transformation (RET)/Papillary Thyroid Carcinoma (PTC) Mol. Endocrinol., December 1, 2007; 21(12): 3039 - 3049. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
